{"nctId":"NCT00377156","briefTitle":"Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases","startDateStruct":{"date":"2006-07","type":"ACTUAL"},"conditions":["Breast Cancer","Cognitive/Functional Effects","Lung Cancer","Metastatic Cancer","Prostate Cancer"],"count":213,"armGroups":[{"label":"Arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: stereotactic radiosurgery"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Radiation: radiation therapy","Radiation: stereotactic radiosurgery"]}],"interventions":[{"name":"radiation therapy","otherNames":[]},{"name":"stereotactic radiosurgery","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of cerebral metastases meeting the following criteria:\n\n  * One to three presumed brain metastases\n  * Metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate)\n\n    * Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s)\n  * Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days\n  * Lesions must not be within 5 mm of the optic chiasm or within the brainstem\n* Eligibility for treatment with gamma knife or linear accelerator-based radiosurgery confirmed by a radiation oncologist\n* No primary germ cell tumor, small cell carcinoma, or lymphoma\n* No leptomeningeal metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Not pregnant\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\n  * Male patients must continue to use contraception for 3 months after the completion of radiotherapy\n* No pacemaker or other MRI-incompatible metal in the body\n* No known allergy to gadolinium\n\nPRIOR CONCURRENT THERAPY:\n\n* More than 7 days since prior and no concurrent chemotherapy\n* No prior cranial radiotherapy\n* No prior resection of cerebral metastases\n* Concurrent hormonal agents, steroids, and/or anticonvulsants allowed","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months","description":"The primary endpoint was cognitive deterioration (progression), defined as a decline of greater than 1 SD from baseline on at least 1 of 7 cognitive tests (all tests are standardized based on published norms and transformed so that higher values represent improved cognition) at the 3-month post-SRS evaluation. The number of participants who experienced cognitive deterioration by 3 months is reported for each arm below. For primary analysis of the 3-month cognitive deterioration endpoint, the Fisher exact 2-group binomial test was used to compare the proportion of evaluable patients with 3-month cognitive deterioration between the 2 groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Local and Distant Tumor Control up to 3 Months","description":"Number of Participants with Local and Distant Tumor Control up to 3 months is defined as....","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Quality of Life, as Measured by Mean Change From Baseline [3 Month]","description":"Quality of Life was assessed using the Functional Assessment of Cancer Therapy-Brain, for which the range is from 0 to 200 and higher scores indicate better QOL. The Quality of Life (QOL) scores were transformed to a 0- to 100-point scale (with 100 being most favorable), in which a 10-point change was considered clinically significant. Intergroup changes in QOL scores were compared using a 2-sample t test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":null},{"groupId":"OG001","value":"-12","spread":null}]}]}]},{"type":"SECONDARY","title":"Long-Term Neurocognitive Status (Long-Term Cognitive Status), as Measured by Percentage of Long-term Survivors With Cognitive Deterioration at 12 Months","description":"Long-Term Neurocognitive Status \\> To ascertain in patients with one to three brain metastases whether there is better long-term neurocognitive status in patients who receive SRS alone (Arm A) compared to patients who receive SRS combined with WBRT (Arm B). Long-term survival status is defined as evaluable patients who survived for at least 12 months and had at least one cognitive assessment on or after 365 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"94.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival, defined as the time from randomization until death due to any cause, was compared between the groups using stratified log-rank tests.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":68},"commonTop":["Alopecia","Nausea","Peripheral motor neuropathy","Cognitive disturbance","Vomiting"]}}}